REALITY试验中晚期启动抗逆转录病毒治疗的晚期就诊者死亡与发病原因及时间分析
在撒哈拉以南非洲CD4<100细胞/µL启动抗逆转录病毒治疗(ART)者中,REALITY随机试验显示强化预防方案较复方磺胺甲噁唑降低死亡率。研究分析1805例参与者死亡/发病原因与时间:48周内225例(12.7%)死亡,事件多发生于早期(中位4周);强化预防降低隐球菌病和不明原因死亡及非致命性结核与隐球菌病。
要点
- CD4<100细胞/µL启动ART者48周死亡率12.7%(225/1805),事件中位4周早期发生。
- 强化预防降低隐球菌病死亡和不明原因死亡(P<.05),未降低结核、严重细菌感染等死亡(P>.3)。
- 强化预防降低非致命/致命结核和隐球菌病(P<.05),未降低严重细菌感染等(P>.2)。
核心结论
- 强化预防降低隐球菌病和不明原因死亡,以及非致命性结核和隐球菌病。
- 致命/非致命事件早期高发,突出晚期疾病启动ART时即应开始强化预防。
研究设计与样本
- REALITY随机试验:参与者CD4计数<100细胞/µL启动ART,强化预防组为复方磺胺甲噁唑加12周异烟肼+氟康唑、单剂阿苯达唑和5天阿奇霉素。
- 盲法委员会判定事件和死因,分类为非互斥的结核、隐球菌病、严重细菌感染(SBI)、其他潜在阿奇霉素反应性感染、其他事件和不明原因。
- 共1805例参与者,ART前中位CD4计数37细胞/µL。
主要发现
- 48周内225例(12.7%)死亡;致命/非致命事件发生早(中位4周),随后发生率指数下降。
- 154例死亡为单一原因,71例为多原因;死因包括结核4.5%、隐球菌病1.1%、SBI 1.9%、其他潜在阿奇霉素反应性感染1.3%、其他事件3.6%、不明原因5.0%。
- 强化预防降低隐球菌病和不明原因死亡(P<.05),未降低结核、SBI、潜在阿奇霉素反应性感染或其他原因死亡(P>.3)。
- 强化预防降低非致命/致命结核和隐球菌病(P<.05),未降低SBI、其他潜在阿奇霉素反应性感染或其他事件(P>.2)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In sub-Saharan Africa, 20%-25% of people starting antiretroviral therapy (ART) have severe immunosuppression; approximately 10% die within 3 months. In the Reduction of EArly mortaLITY (REALITY) randomized trial, a broad enhanced anti-infection prophylaxis bundle reduced mortality vs cotrimoxazole. We investigate the contribution and timing of different causes of mortality/morbidity. METHODS: Participants started ART with a CD4 count <100 cells/µL; enhanced prophylaxis comprised cotrimoxazole plus 12 weeks of isoniazid + fluconazole, single-dose albendazole, and 5 days of azithromycin. A blinded committee adjudicated events and causes of death as (non-mutually exclusively) tuberculosis, cryptococcosis, severe bacterial infection (SBI), other potentially azithromycin-responsive infections, other events, and unknown. RESULTS: Median pre-ART CD4 count was 37 cells/µL. Among 1805 participants, 225 (12.7%) died by week 48. Fatal/nonfatal events occurred early (median 4 weeks); rates then declined exponentially. One hundred fifty-four deaths had single and 71 had multiple causes, including tuberculosis in 4.5% participants, cryptococcosis in 1.1%, SBI in 1.9%, other potentially azithromycin-responsive infections in 1.3%, other events in 3.6%, and unknown in 5.0%. Enhanced prophylaxis reduced deaths from cryptococcosis and unknown causes (P < .05) but not tuberculosis, SBI, potentially azithromycin-responsive infections, or other causes (P > .3); and reduced nonfatal/fatal tuberculosis and cryptococcosis (P < .05), but not SBI, other potentially azithromycin-responsive infections, or other events (P > .2). CONCLUSIONS: Enhanced prophylaxis reduced mortality from cryptococcosis and unknown causes and nonfatal tuberculosis and cryptococcosis. High early incidence of fatal/nonfatal events highlights the need for starting enhanced-prophylaxis with ART in advanced disease. CLINICAL TRIALS REGISTRATION: ISRCTN43622374.
引用
- Post FA, Szubert AJ, Prendergast AJ, et al. Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial. Clin Infect Dis. 2018. PMID: 29514234. doi:10.1093/cid/cix1141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。